Analysts Expect Minerva Neurosciences Inc (NASDAQ:NERV) to Announce -$0.42 EPS

Wall Street brokerages expect that Minerva Neurosciences Inc (NASDAQ:NERV) will post ($0.42) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences posted earnings of ($0.32) per share during the same quarter last year, which indicates a negative year over year growth rate of 31.3%. The business is scheduled to report its next quarterly earnings report before the market opens on Monday, August 5th.

According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.71) per share for the current fiscal year, with EPS estimates ranging from ($1.79) to ($1.62). For the next financial year, analysts expect that the firm will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.31) to ($2.01). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06).

NERV has been the subject of several research reports. ValuEngine upgraded shares of ZIX from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 4th. HC Wainwright set a $25.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research report on Friday, May 31st. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. Finally, BidaskClub upgraded shares of Acceleron Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, May 10th.

In other Minerva Neurosciences news, major shareholder Venture Associates L. Index III sold 36,574 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $7.05, for a total transaction of $257,846.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Venture Associates L. Index III sold 110,818 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $4.41, for a total transaction of $488,707.38. The disclosure for this sale can be found here. Insiders sold 670,558 shares of company stock valued at $3,694,870 over the last quarter. 12.00% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its position in Minerva Neurosciences by 63,940.0% during the first quarter. BNP Paribas Arbitrage SA now owns 6,404 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 6,394 shares during the period. Quantitative Systematic Strategies LLC purchased a new stake in Minerva Neurosciences during the second quarter valued at about $62,000. Prudential Financial Inc. purchased a new stake in Minerva Neurosciences during the fourth quarter valued at about $77,000. Metropolitan Life Insurance Co. NY boosted its position in Minerva Neurosciences by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,515 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 8,993 shares during the period. Finally, Algert Global LLC purchased a new stake in Minerva Neurosciences during the first quarter valued at about $120,000. Institutional investors and hedge funds own 77.01% of the company’s stock.

Shares of Minerva Neurosciences stock traded up $0.06 during trading on Wednesday, hitting $6.63. The stock had a trading volume of 7,170 shares, compared to its average volume of 388,176. Minerva Neurosciences has a 12 month low of $4.07 and a 12 month high of $12.95. The company’s 50-day moving average price is $5.84. The stock has a market capitalization of $252.88 million, a price-to-earnings ratio of -5.17 and a beta of 1.59.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Read More: Coverage Ratio

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.